Publications:

Astrof S, Crowley D, Hynes RO.
Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectin.
Dev Biol. 2007 Jul 12;

Astrof S, Kirby A, Lindblad-Toh K, Daly M, Hynes RO.
Heart development in fibronectin-null mice is governed by a genetic modifier on chromosome four.
Mech Dev. 2007 Aug;124(7-8):551-8.

Matuskova J, Chauhan AK, Cambien B, Astrof S, Dole VS, Piffath CL, Hynes RO, Wagner DD. Decreased plasma fibronectin leads to delayed thrombus growth in injured arterioles. Arterioscler Thromb Vasc Biol. 2006 Jun; 26(6):1391-6.

Astrof S, Crowley D, George EL, Fukuda T, Sekiguchi K, Hanahan D, Hynes RO.
Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis.
Mol Cell Biol. 2004 Oct;24(19):8662-70.

Other published work (under the name of Snitkovsky):

Snitkovsky S and Young JAT. Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein. Proc Natl Acad Sci U S A. 1998 Jun 9; 95(12): 7063-8

Boerger AL, Snitkovsky S, Young JAT. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc Natl Acad Sci U S A. 1999 Aug 17; 96(17): 9867-72

Snitkovsky S, Niederman TM, Carter BS, Mulligan RC, Young JAT. A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor. J Virol. 2000 Oct; 74(20): 9540-5

Snitkovsky, S, Niederman TM, Mulligan RC, Young JAT. Targeting avian leukosis virus subgroup A vectors by using a TVA-VEGF bridge protein. J Virol. 2001 Feb; 75(3): 1571-5

Snitkovsky S and Young JAT. Targeting retroviral vector infection to cells that express heregulin receptors using a TVA-heregulin bridge protein. Virology. 2002 Jan 5; 292(1): 150-5